ARTICLE | Company News
Hawthorn, University of Pittsburgh deal
May 24, 2010 7:00 AM UTC
Hawthorn received exclusive, worldwide rights to the university's mAbs against melanoma-associated chondroitin sulfate proteoglycan ( MCSP; CSPG4). The university is eligible for milestones and roya...